As HOXD9 deregulates histone methylation by PRC2 in cholangiocarcinogenesis, using histone methyltransferase inhibitors to block PCR2 and reactivate silenced HOX genes like HOXD9 could represent a potential epigenetic therapy approach for Ov-CCA. Here, HOXD9 is linked to cholangiocarcinoma.